Pfizer's Lorbrena Wins Full FDA Approval As First Line Treatment Of ALK-Positive Lung Cancer

Loading...
Loading...

The FDA has approved Pfizer Inc's (NYSE: PFE) supplemental application seeking approval for Lorbrena (lorlatinib), expanding the indication to include first-line treatment of people with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC).

  • The FDA action also converts 2018 accelerated approval to full approval.
  • In 2018 Lorbrena was approved for patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy.
  • The approval is based on the CROWN trial, which showed a 72% reduction in risk of progression or death for treatment with Lorbrena vs. Xalkori, recognized as the first-line standard of care for patients with ALK-positive advanced NSCLC.
  • Price Action: PFE shares are down 0.4% at $34.25 in premarket trading on the last check Thursday.
Posted In: BiotechNewsHealth CareFDAGeneralNon-Small Cell Lung Cancer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...